What have we learned in the era of NOACs.

4 March 2018 (11:36 - 11:54)

Organised by:

Video

Slides

Sign in for access options

About the speaker

Professor Freek Verheugt

Hospital Onze Lieve Vrouwe Gasthuis, Amsterdam (Netherlands (The))

4 More presentations in this session

Presentation thumbnail

Why do we need to combine antiplatelets and anticoagulants?

Professor R. De Caterina (Pisa, IT)

Presentation thumbnail

Rational to remove aspirin from the cocktail. The story after WOEST...(VIA ZOOM)

Professor J. ten Berg (Nieuwegein, NL)

Presentation thumbnail

Type of stent, type of antiplatelet, type of anticoagulant. The triad of success.

Doctor G. Casella (Bologna, IT)

Presentation thumbnail

Ultra-low-dose twice-daily aspirin improves haemostasis and maintains platelet inhibition in acute coronary syndrome patients receiving ticagrelor

Doctor W. Parker (Sheffield, GB)

Abstract Slides Video

Access the full session

Session thumbnail

Anti-thrombotics in patients at simultaneous risk of stroke and stent thrombosis

The Event

Acute Cardiovascular Care 2018

4 March 2018 11:36 CET

You may be interested in

Webinar

Are NOACs already outdated? New trends in anticoagulation therapy

12 December 2022

Congress Presentation

The prevalence and safety of direct oral anticoagulants in patients with non-atrial fibrillation associated intra-cardiac thrombus

27 August 2021

Congress Presentation

Adherence and treatment satisfaction among atrial fibrillation patients treated with VKAs versus NOACs: real-world data from a single-center cohort

12 April 2026

Congress Session

Stroke prevention in atrial fibrillation: do not forget the left atrial appendage!

31 March 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources